Skip to main content
. 2018 May 25;14(2):278–287. doi: 10.2215/CJN.02170218

Table 2.

Additional pharmacokinetic properties in those with normal kidney function

OAC Cmax, h t1/2, h Protein binding, % VD, L Bioavailability, %
Warfarin 2–6 42 97–99 10 99
Dabigatran 1–2 12–14 38 50–70 3–7
Apixaban 3–4 12 87 21 50
Rivaroxaban 2–4 6–13 >90 50 66–100
Edoxaban 1–2 10–14 55 107 62

OAC, oral anticoagulant; Cmax, peak concentration; VD, volume of distribution.